Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, April 7, 2025

Comparative analysis of stroke burden between ages 20–54 and over 55 years: based on the global burden of disease study 2019

 Useless piece of research! Solve stroke instead of telling us how bad it is! I'D HAVE YOU ALL FIRED!

Comparative analysis of stroke burden between ages 20–54 and over 55 years: based on the global burden of disease study 2019

Abstract

Background

Stroke remains one of the major diseases threatening human health and life worldwide. Therefore, it is urgent to investigate the stroke burden in different age groups.

Methods

We described the disease burden of three subtypes of stroke, namely intracranial haemorrhage (ICH), subarachnoid haemorrhage (SAH), and ischaemic stroke (IS), among people aged 20 ~ 54 years and > 55 years from 1990 to 2019, based on data from Global Burden of Disease Study 2019 and calculated the estimated annual percentage changes (EAPC) for age-specific incidence, disability-adjusted life-years (DALYs), mortality and prevalence rates. Joinpoint regression analyzes showed the critical years of trend inflexion points. Decomposition and health inequality analyses determined the impact of different epidemiological factors on stroke burden. Population-attributable fractions were calculated for deaths and DALYs due to risk factors.

Results

From 1990 to 2019, the incidence of ICH and SAH decreased by 11.32% and 10.45%, respectively, in the 20–54 age group globally, while the incidence of IS increased by 14.95%. Meanwhile, the incidence of stroke in the > 55 years group showed an overall decreasing trend. The burden of adverse outcomes, including death and DALYs, varied by stroke subtype, with the rates of mortality and DALYs decreasing significantly less in IS than in ICH and SAH. In addition, the decline in mortality and DALYs rates was consistently greater in the over 55 years age group than in the 20–54 years age group. Notably, the prevalence of ICH, SAH, and IS increased by 20.55%, 11.50%, and 7.38% in the 20–54 years age grouper group, respectively, whereas in the elderly group, there was only a mild increase of IS in the over 55 years group. What is more, stroke burden showed a negative correlation with regional development. Furthermore, high systolic blood pressure was a common contributor to stroke burden in both age groups. The difference is that a high body mass index affects people aged 20–54 years more, while abnormal fasting blood glucose affects older people more.

Conclusion

The stroke burden in people 20–54 years of age is increasingly becoming a global health problem, particularly the incidence of IS in lower economic development areas.

Clinical trial number

Not applicable.

No comments:

Post a Comment